SSB
NKTR icon

Sandy Spring Bank’s Nektar Therapeutics NKTR Stock Holding History

Sandy Spring Bank’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-110
Closed -$27K – 1026
2020
Q3 		$27K Sell
110
-10
-8% -$3.15K ﹤0.01% 553
2020
Q2 		$42K Hold
120
– – ﹤0.01% 479
2020
Q1 		$32K Hold
120
– – ﹤0.01% 505
2019
Q4 		$39K Hold
120
– – ﹤0.01% 510
2019
Q3 		$33K Hold
120
– – ﹤0.01% 535
2019
Q2 		$64K Hold
120
– – 0.01% 430
2019
Q1 		$60K Hold
120
– – 0.01% 421
2018
Q4 		$59K Buy
+120
New +$72.4K 0.01% 422

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sandy Spring Bank's NKTR Position: Q4 2020 in Review

Sandy Spring Bank sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 110 shares — an estimated $27K sold.

Sandy Spring Bank first reported a position in NKTR in Q4 2018 and held it in 8 quarters. The position peaked at $64K in Q2 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Sandy Spring Bank reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Sandy Spring Bank sold 110 Nektar Therapeutics shares in Q4 2020, an estimated $27K.
  • Sandy Spring Bank first reported a position in Nektar Therapeutics in Q4 2018 and held it in 8 quarters.
  • Sandy Spring Bank's Nektar Therapeutics position peaked at $64K in Q2 2019.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Sandy Spring Bank's 13F filing for Q4 2020, filed 3 Feb 2021.